-

Miley Cyrus Joins Hims & Hers as Creative Advisor

Company Is Teaming Up With The Multi-Platinum Selling Recording Artist, Songwriter and Trailblazer to Shine a Spotlight On Personalized Skincare

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers, the multi-specialty telehealth platform that provides modern personalized health and wellness experiences to consumers, today announced Multi-Platinum Selling Recording Artist, Songwriter and Trailblazer Miley Cyrus has joined the Company as a Creative Advisor. In this role, the icon of authenticity will collaborate with the Company on the Hers line of prescription skincare products, beginning with a series of new advertising campaigns and social content.

“While I struggled a lot with my skin when I was younger, I’ve learned that there isn’t a one-size-fits-all skincare routine -- it needs to be personalized,” commented Miley Cyrus. “Hims & Hers makes the entire process incredibly simple, from the initial virtual consultation to the monthly subscription of products tailored just for me. In this new advisory role, I hope to work closely with the company and introduce my fans to an easier, more personalized skincare journey.”

Hims & Hers, which recently began trading on the New York Stock Exchange, offers personalized, high-quality solutions for issues related to primary care as well as mental health, sexual wellness, hair loss and skincare to a digitally native generation. The brand’s current selection of medical skincare services includes free telehealth consultations with licensed medical professionals discussing concerns such as acne and anti-aging, a suite of customizable prescription products and a collection of nonprescription options. The prescription skincare products available through Hers harness powerful ingredients such as tretinoin, clindamycin, azelaic acid, zinc pyrithione, and niacinamide in beautiful, easy-to-use packaging for a low monthly cost.

“For many consumers, skincare routines particularly related to acne or aging can feel daunting and ineffective,” noted Co-Founder and CEO Andrew Dudum. “We’re thrilled to have Miley, who is an incredibly outspoken and passionate businesswoman in her own right, supporting our efforts to bring personalized skincare to a larger audience.”

For additional details on the Hims & Hers skincare offering or to learn more about the brand’s partnership with Miley Cyrus, please visit www.forhers.com.

About Hims & Hers

Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide access to quality, convenient and affordable care for all Americans. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Contacts

Linda O'Connor
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Summary
Miley Cyrus has joined Hims & Hers as a Creative Advisor beginning with a series of new advertising campaigns and social content.
Release Versions

Contacts

Linda O'Connor
press@forhims.com

More News From Hims & Hers

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. By leveraging nearly a decade of infrastructur...

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

SAN FRANCISCO--(BUSINESS WIRE)--Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care....

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa...
Back to Newsroom